Lexicon Pharmaceuticals Inc. kicked off the trading day on 10/10/19 with a price increase of 1.20%, equivalent to $0.04 relative change for the day. Taking a more long-term approach, LXRX had a 52-week range of $1.13 to $9.33. At the time of this article’s publishing, this stock is trading at $3.37 after starting the trading session at $3.29. At the time of writing, this stock’s 50-day Moving Average stands at $2.17, while the 200-day Moving Average of this stock is currently $4.99.
Currently, this company’s share volume is sitting at $1322539, but has maintained average daily volume of $2.49M. This stock has generated an average Year to Date volume of $1.3 million, alongside an average 20-day volume of $3.35 million. This publicly-traded company’s shares outstanding now amounts to $106.27 million, simultaneously with a float of $105.26 million. The organization now has a market capitalization sitting at $358.14 million.
Lexicon Pharmaceuticals Inc.(LXRX) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Lexicon Pharmaceuticals Inc.’s current insider ownership accounts for 0.80%, in contrast to 99.80% institutional ownership. According to the most recent latest insider trade that took place on Sep 18 this organization’s President and CEO bought 50,000 at the rate of 3.10, making the entire transaction hit 155,000 in total value, affecting insider ownership by 227,539. Preceding that transaction, on Sep 18 Company’s EVP and CCO bought 4,500 at a price of 3.36, making the whole transaction’s value amount to 15,115. This particular insider is now the holder of 18,661 in total.
If we take a glance at the Ownership summary of Lexicon Pharmaceuticals Inc.’s stock, Institutional holders make up 99.80% of its total stock ownership. All together, they are the legal holders of 106.27M shares. If we focus on the top 3 stockholders for this publicly-traded organization, Invus Public Equities Advisors LLC owns 60,240,864 shares, with Fidelity Management & Research Co. in 2nd place owning 13,488,094 shares and Ulys LLC in third place with total ownership of 4,321,214 shares.
Lexicon Pharmaceuticals Inc. (LXRX) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 6/29/2019, the organization reported -$0.22 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$0.08) by -$0.14.
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
Lexicon Pharmaceuticals Inc.’s EPS increase for this current 12-month fiscal period is 5.60%, and is forecasted to reach -1.27 in the upcoming year.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Lexicon Pharmaceuticals Inc., this organization’s Quick Ratio in the last reported quarter now stands at 5.30. The company has managed to achieve an average true range (ATR) of 0.39. Alongside those, its Beta score is 0.85.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.31 for this organization.
In the same vein, LXRX’s Diluted EPS (Earnings per Share) trailing twelve months was posted at -0.84, a figure that is expected to reach 0.73 in the next reported quarter, and analysts expect it will be -1.27 at the market close of one year from today’s date.